Delving into the Latest Updates on Barnidipine Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Barnidipine, Barnidipine hydrochloride (JAN), Cyress

+ [15]

Target

Cav2.1

Mechanism

Cav2.1 inhibitors(calcium voltage-gated channel subunit alpha1 A inhibitors)

Therapeutic Areas

Cardiovascular DiseasesUrogenital Diseases

Active Indication

Hypertension, RenovascularParenchymal renal hypertensionHypertension

Inactive Indication-

Originator Organization

Japan Established Medicine Corp

Active Organization

LTL Pharma Co., Ltd.

Daiichi Sankyo Co., Ltd.Japan Established Medicine Corp

+ [1]

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (01 Jan 1992),

Hypertension

Regulation-

Login to view timeline

Structure

Molecular FormulaC27H30ClN3O6

InChIKeyXEMPUKIZUCIZEY-YSCHMLPRSA-N

CAS Registry104757-53-1

View All Structures (2)

AbstractAn experimental combination of analytical quality by design and green analytical chemistry approaches is introduced to develop an high‐performance thin‐layer chromatography (HPTLC) approach to quantify barnidipine hydrochloride in the pharmaceutical matrix. The analytical quality by design approach was introduced to green analytical chemistry to enhance protocol knowledge while ensuring efficiency and reducing environmental impacts, energy consumption and analyst visibility. This analytical approach was systematically addressed by exploring failure mode effect analysis, risk assessment and optimization design. Subsequently, a screening of primary variables was performed to select the aptest proportion of solvents in the mobile phase resulting from the principles of green analytical chemistry. Failure mode effect analysis and a risk assessment study were attempted to estimate the critical method parameters (CMPs). The influence of the CMPs on critical analytical attributes, i.e. retention factor and peak area, was assessed through a screening design. A response surface methodology was then executed for the critical analytical attributes as a concern of the determined CMPs, and the conditions for excellent resolution were determined using a desirability procedure. The established protocol was validated in compliance with the International Conference on Harmonization guideline Q2(R1) and showed excellent specificity and sensitivity.

01 Aug 2021·Future Medicinal ChemistryQ4 · MEDICINE

Computational Drug Repositioning for Ischemic Stroke: Neuroprotective Drug Discovery

Q4 · MEDICINE

Article

Author: Chen, Xiujie ; Bender, Andreas ; Zhang, Yan ; Meng, Qingkang ; Li, Yunong ; Yang, Jingbo

Background: A comprehensive approach to drug repositioning will be required to overcome translational hurdles and identify more neuroprotective drugs. Results & methods: Gene Set Enrichment Analysis was applied to identify related pathways and enriched genes. Candidate genes were optimized using ToppGene, ToppGenet and pBRIT. From the perspective of the local structures, gene–domain–substructure–drug relationships were constructed. Using the MCODE algorithm and K-means clustering, 31 functional subnetworks were obtained, and 252 drugs with proposed neuroprotective function were identified. Using computational analysis, 72 substructures with different scores were found to correspond to neuroprotective functions. The protective effects of benidipine and barnidipine were confirmed in vitro. Conclusion: The authors' research has great potential to discover more neuroprotective drugs and obtain more information regarding mechanisms of action and functional substructures.

01 Jan 2021·Archives of Medical ResearchQ4 · MEDICINE

Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study

Q4 · MEDICINE

Article

Author: Baby, Krishnaprasad ; Nayak, Usha Y ; Suresh, Akhil ; Nayak, Yogendra ; Maity, Swastika ; Mehta, Chetan H

BACKGROUND AND AIMSSevere Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) induced Novel Coronavirus Disease (COVID-19) has currently become pandemic worldwide. Though drugs like remdesivir, favipiravir, and dexamethasone found beneficial for COVID-19 management, they have limitations clinically, and vaccine development takes a long time. The researchers have reported key proteins which could act as druggable targets. Among them, the major protease M^pro is first published, plays a prominent role in viral replication and an attractive drug-target for drug discovery. Hence, to target M^pro and inhibit it, we accomplished the virtual screening of US-FDA approved drugs using well-known drug repurposing approach by computer-aided tools.METHODSThe protein M^pro, PDB-ID 6LU7 was imported to Maestro graphical user interphase of Schrödinger software. The US-FDA approved drug structures are imported from DrugBank and docked after preliminary protein and ligand preparation. The drugs are shortlisted based on the docking scores in the Standard Precision method (SP-docking) and then based on the type of molecular interactions they are studied for molecular dynamics simulations.RESULTSThe docking and molecular interactions studies, five drugs emerged as potential hits by forming hydrophilic, hydrophobic, electrostatic interactions. The drugs such as arbutin, terbutaline, barnidipine, tipiracil and aprepitant identified as potential hits. Among the drugs, tipiracil and aprepitant interacted with the M^pro consistently, and they turned out to be most promising.CONCLUSIONSThis study shows the possible exploration for drug repurposing using computer-aided docking tools and the potential roles of tipiracil and aprepitant, which can be explored further in the treatment of COVID-19.

100 Deals associated with Barnidipine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01104	Barnidipine Hydrochloride	C08CA12	DB09227

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hypertension, Renovascular	JP	LTL Pharma Co., Ltd.	07 Sep 1994
Parenchymal renal hypertension	JP	LTL Pharma Co., Ltd.	03 Jul 1992
Hypertension	JP	Japan Established Medicine Corp	01 Jan 1992

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EULAR2024	Not Applicable	Scleroderma, Systemic	-	Barnidipine 10mg/day	jljqennseb(gtbggnfgpl) = The two groups had a similar incidence of AEs leading to discontinuation (20.1 vs 17%), the most commonly reported being headache (38.5%), hypotension (30.8%), palpitations, flushing, and edema (7.7% each). No serious AE was reported in any group. gzgcczloap (aujpgifpiv )	-	05 Jun 2024
				MR-nifedipine 20mg/day
ASN2014	Not Applicable	Hypertension aldosterone \| renin \| cortisol ... View more	-	Spironolactone 50mg	(wyfdfiqygo) = ybccdeegel zdmtpgwsel (vzptjrbzbg, 10.8)	Positive	11 Nov 2014
				Barnidipine 15mg	(wyfdfiqygo) = wlfgrzseff zdmtpgwsel (vzptjrbzbg, 13.8)